Blog
May 14, 2026
The power of one: How assay consolidation and menu expansion reshape sequencing economics
Genomic testing has historically evolved around limitations. Different technologies were developed to answer different questions, and over time, laboratories built workflows that stitched those answers together. The result is…
May 8, 2026
Long-read sequencing is not the trade-off it used to be: These are the 5 questions that show why
By Samantha Kalla, Field Application Scientist, PacBio For years, five variables have defined the trade-offs in sequencing: read length, accuracy, methylation, cost, and sample input. Pick long reads, accept…
April 17, 2026
From genome to therapy: How HiFi long-read sequencing is helping to accelerate next-generation cancer drug research and development
Today’s cancer drug development has evolved far beyond traditional chemotherapies. Curre oncology pipeline includes precision small molecules, monoclonal antibodies, antibody-drug conjugates (ADCs), CAR-T therapies, TCR-engineered cells, and personalized cancer…
March 25, 2026
2025 Immunology and Immunotherapy SMRT Grant winners announced
Accurately capturing immune diversity is critical to advancing our understanding of disease mechanisms and enabling the development of more precise and effective therapies. However, conventional immune profiling technologies lack…